E Rostholder1, A Ahmed, A S Cheifetz, A C Moss. 1. Center for Inflammatory Bowel Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Infliximab (IFX) therapy escalation during maintenance treatment occurs frequently in clinical practice in patients with ulcerative colitis (UC). Outcomes for these patients have not been described. AIM: To describe the prevalence of, and outcomes after, IFX escalation during maintenance therapy in patients with moderate-severe UC. METHODS: Retrospective observational study of clinical outcomes in ambulatory patients with moderate-severe UC treated with maintenance IFX. RESULTS: Fifty-six ambulatory patients received IFX for moderate-severe UC; fifty (89%) responded and proceeded to maintenance therapy. Mean duration of maintenance therapy was 14 months, with mean follow-up of 38 months. Twenty-seven patients (54%) required IFX therapy escalation after a mean of six maintenance infusions. Clinical remission was noted in 36% of the entire cohort (18/50) at 12 months; 19% in the escalation group and 56% in the non-escalation group. Patients who required IFX escalation were less likely to be in clinical remission at 12 months (OR 0.2, 95% CI 0.1-0.6, P = 0.01) when compared with those who did not. During the follow-up period, 27% of patients required a colectomy, and the mean time to colectomy was 17 months. Patients in the escalation group required a colectomy in 33% of cases, compared with 21% of non-escalation patients. CONCLUSIONS: A significant proportion of ambulatory patients with UC treated with maintenance infliximab required therapy escalation over time. This was associated with lower remission, and higher colectomy, rates.
BACKGROUND:Infliximab (IFX) therapy escalation during maintenance treatment occurs frequently in clinical practice in patients with ulcerative colitis (UC). Outcomes for these patients have not been described. AIM: To describe the prevalence of, and outcomes after, IFX escalation during maintenance therapy in patients with moderate-severe UC. METHODS: Retrospective observational study of clinical outcomes in ambulatory patients with moderate-severe UC treated with maintenance IFX. RESULTS: Fifty-six ambulatory patients received IFX for moderate-severe UC; fifty (89%) responded and proceeded to maintenance therapy. Mean duration of maintenance therapy was 14 months, with mean follow-up of 38 months. Twenty-seven patients (54%) required IFX therapy escalation after a mean of six maintenance infusions. Clinical remission was noted in 36% of the entire cohort (18/50) at 12 months; 19% in the escalation group and 56% in the non-escalation group. Patients who required IFX escalation were less likely to be in clinical remission at 12 months (OR 0.2, 95% CI 0.1-0.6, P = 0.01) when compared with those who did not. During the follow-up period, 27% of patients required a colectomy, and the mean time to colectomy was 17 months. Patients in the escalation group required a colectomy in 33% of cases, compared with 21% of non-escalation patients. CONCLUSIONS: A significant proportion of ambulatory patients with UC treated with maintenance infliximab required therapy escalation over time. This was associated with lower remission, and higher colectomy, rates.
Authors: Gil Y Melmed; Brennan M Spiegel; Brian Bressler; Adam S Cheifetz; Shane M Devlin; Laura E Harrell; Peter M Irving; Jennifer Jones; Gilaad G Kaplan; Patricia L Kozuch; Fernando S Velayos; Leonard Baidoo; Miles P Sparrow; Corey A Siegel Journal: Clin Gastroenterol Hepatol Date: 2010-05-06 Impact factor: 11.382
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Heidi Waters; Julie Vanderpoel; Scott McKenzie; Orsolya Lunacsek; Meg Franklin; Barbara Lennert; John Goff; Damian H Augustyn Journal: J Med Econ Date: 2011-05-19 Impact factor: 2.448
Authors: Y Zabana; E Domènech; M Mañosa; E Garcia-Planella; I Bernal; E Cabré; M A Gassull Journal: Aliment Pharmacol Ther Date: 2009-11-30 Impact factor: 8.171
Authors: G R Lichtenstein; R H Diamond; C L Wagner; A A Fasanmade; A D Olson; C W Marano; J Johanns; Y Lang; W J Sandborn Journal: Aliment Pharmacol Ther Date: 2009-04-21 Impact factor: 8.171
Authors: Carlos Taxonera; Manuel Barreiro-de Acosta; Marta Calvo; Cristina Saro; Guillermo Bastida; María D Martín-Arranz; Javier P Gisbert; Valle García-Sánchez; Ignacio Marín-Jiménez; Fernando Bermejo; María Chaparro; Ángel Ponferrada; María P Martínez-Montiel; Ramón Pajares; Celia de Gracia; David Olivares; Cristina Alba; Juan L Mendoza; Ignacio Fernández-Blanco Journal: Dig Dis Sci Date: 2015-06-05 Impact factor: 3.199
Authors: Carlos Taxonera; David Olivares; Juan L Mendoza; Manuel Díaz-Rubio; Enrique Rey Journal: World J Gastroenterol Date: 2014-07-21 Impact factor: 5.742